Konstantin Konstantinov, Ph.D., has served as a director of Repligen since May 2022. He has also been a member of Repligen's Scientific Advisory Board since March 2016. Dr. Konstantinov is currently Chief Technology Officer at Ring Therapeutics and Operating Partner at Flagship Pioneering.
Dr. Konstantinov previously served as Chief Technology Officer at Codiak BioSciences. Before joining Codiak, he was responsible for the late-stage bioprocess and technology development at Sanofi's Boston hub, including all functions from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California, advancing to the position of Head of Process Sciences.
He has published 60 peer reviewed papers and has more than 15 patents and patent applications. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, followed by a post-doctoral assignment at DuPont and the University of Delaware.